Teaching an Old Drug a New Trick: Targeting Treatment Resistance in Genitourinary Cancers

• DOI: 10.33696/signaling.5.112
• Publication Date: 2024-05-07T13:08:02Z
• Authors: Karina Aguilar; Anuj K. Sharma; Tianyu Yang; Dipen Mehta; Chandramukhi S. P...; Vinata B. Lokeshwar

In the quest for improving clinical outcome of patients with metastatic genitourinary cancers, including renal cell carcinoma (mRCC), emphasis often is on finding new targeted therapies. However, two studies by Jordan et al. (Oncogenesis 2020) and Wang (Cancer Cell Int 2022) demonstrate feasibility efficacy a modestly effective drug Sorafenib against mRCC attacking mechanism hijacked RCC cells inactivating Sorafenib. The also identified hyaluronic acid synthase -3 (HAS3) as bonafide target in cells. that an over-the-counter Hymecromone (4-methylumbelliferone) blocks inactivation improves its through inhibition HAS3 expression HA signaling. broader context, “old failed drugs” have favorable safety profiles should increase availability treatments advanced cancers.